G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9 USD 3.93% Market Closed
Market Cap: 558.3m USD

Profitability Summary

GH Research PLC's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
GH Research PLC

Revenue
0 USD
Operating Expenses
-50.3m USD
Operating Income
-50.3m USD
Other Expenses
11.4m USD
Net Income
-39m USD

Margins Comparison
GH Research PLC Competitors

Country Company Market Cap Operating
Margin
Net
Margin
IE
GH Research PLC
NASDAQ:GHRS
558.3m USD N/A N/A
US
Eli Lilly and Co
NYSE:LLY
694B USD
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
365.2B USD
26%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
48%
35%
CH
Roche Holding AG
SIX:ROG
194.4B CHF
32%
20%
CH
Novartis AG
SIX:NOVN
174.3B CHF
32%
23%
UK
AstraZeneca PLC
LSE:AZN
155.2B GBP
23%
13%
US
Merck & Co Inc
NYSE:MRK
200.5B USD
36%
27%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
11%
-126%
FR
Sanofi SA
PAR:SAN
111.8B EUR
21%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
GH Research PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IE
GH Research PLC
NASDAQ:GHRS
558.3m USD
-20%
-19%
-25%
-104%
US
Eli Lilly and Co
NYSE:LLY
694B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
365.2B USD
20%
8%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
194.4B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
174.3B CHF
27%
12%
23%
17%
UK
AstraZeneca PLC
LSE:AZN
155.2B GBP
18%
7%
17%
14%
US
Merck & Co Inc
NYSE:MRK
200.5B USD
42%
15%
28%
21%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
70%
-51%
5%
6%
FR
Sanofi SA
PAR:SAN
111.8B EUR
8%
4%
9%
7%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less